Free Trial
NASDAQ:ELEV

Elevation Oncology Q4 2023 Earnings Report

Elevation Oncology logo
$0.34 -0.01 (-3.14%)
As of 12:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elevation Oncology EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.21
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Elevation Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elevation Oncology Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, March 6, 2024
Conference Call Time
7:00AM ET

Elevation Oncology Earnings Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Elevation Oncology (ELEV) Gets a Hold from Leerink Partners
See More Elevation Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elevation Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elevation Oncology and other key companies, straight to your email.

About Elevation Oncology

Elevation Oncology (NASDAQ:ELEV), an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

View Elevation Oncology Profile

More Earnings Resources from MarketBeat